[ad_1]
\n<\/p>\n
J&J and <\/span><\/span><\/span><\/span><\/span><\/span>Regeneron<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> will be some of the first tenants of Fujifilm Biotechnologies\u2019 Holly Springs facility when it opens later this year.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n The recent deal allows J&J to manufacture \u201cthe vast majority\u201d of its advanced medicines in the United States to meet national demand, the New Brunswick, New Jersey-based company said. <\/strong>J&J manufactures medicines for the oncology, immunology, neuroscience and cardiopulmonary fields, according to its website<\/a>.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n Currently, J&J operates 23 U.S. facilities, comprising about a third of its global manufacturing footprint, according to its <\/span><\/span><\/span><\/span><\/span><\/span>2024 annual report<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a>. The company has been building out its domestic operations as tariffs complicate international trade and more tax incentives become available for manufacturers that do business in the U.S.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n \u201cIt’s hard to know what is going to happen ultimately with tariffs,\u201d <\/span><\/span><\/span><\/span><\/span><\/span>J&J CEO Joaquin Duato said during a July 16 earnings call.<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> \u201cBut what we do know for sure is that the tax policies that just passed are already creating American jobs and driving innovation.\u201d<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n The current administration’s tax law enhanced manufacturers\u2019 <\/span><\/span><\/span><\/span><\/span><\/span>ability to deduct business expenses<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> for costs related to domestic R&D and certain production properties.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n Fujifilm Biotechnologies\u2019 Holly Springs facility will be the company\u2019s largest cell culture biopharmaceutical facility for <\/span><\/span><\/span><\/span><\/span><\/span>contract development and manufacturing organization<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a>\u00a0manufacturing in North America, according to its website. Parent company Fujifilm has invested more than <\/span><\/span><\/span><\/span><\/span><\/span>$3.2 billion<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> into the project so far, with plans to bring 1,400 jobs to the area by 2031.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n Earlier this year, Regeneron, a manufacturer of large bulk drugs, inked a $3 billion supply deal with\u00a0<\/strong>Fujifilm Biotechnologies that is expected to nearly double its U.S. manufacturing capacity as tariffs stir global tensions.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n Last month, President Donald Trump <\/span><\/span><\/span><\/span><\/span><\/span>threatened tariffs of up to 250%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> on pharmaceutical imports over the next year and a half. However, this is likely to vary by country. Most recently, the U.S. struck a deal to cap its tariffs at <\/span><\/span><\/span><\/span><\/span><\/span>15% for EU pharmaceuticals<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a>.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n In addition to the deal with Fujifilm Biotechnologies, J&J is moving forward with other U.S. projects, including construction of its <\/span><\/span><\/span><\/span><\/span><\/span>$2-billion-plus facility<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/a> in Wilson, North Carolina. It is also investing in R&D infrastructure aimed at developing lifesaving treatments in oncology, neuroscience and other areas of study, according to the Aug. 21 news release.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<\/p><\/div>\n [ad_2]